Lili Pan

Also affiliated with Fujian Provincial Hospital, Union Hospital

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non–Small Cell Lung Cancer”.

FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non–Small Cell Lung Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0949

N/A

0DataRank · unranked

14 citations

Diana Bradford, Yi Ren, Stephanie Aungst, Claudia P. Miller, Lili Pan +19 more

FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase 1 Mutation

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-2196

N/A

0DataRank · unranked

10 citations

Kelly J. Norsworthy, Moran Choe, Brenda J. Gehrke, Haiyan Chen, Jonathon Vallejo +12 more

FDA Approval Summary: Capecitabine Labeling Update under Project Renewal

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1708

N/A

0DataRank · unranked

3 citations

C S Lee, William F. Pierce, Elizabeth Everhart, Adriene King-Ducre, Melanie Royce +13 more